

#### Publishable Summary

This quarterly report aims at providing detailed information on the progress of the AMYPAD Diagnostic and Patient Management study with a specific focus on the progress achieved during the fourth and last quarter of 2019. The report shows the fast increase in the recruitment of patients in all eight active sites as expected.

The addition of Lausanne (CHUV) and Stockholm (KI) to the already active sites had a significant impact in increasing the recruitment rate during the last quarter of 2019, with 60 patients recruited in October, 57 in November and 30 in December in spite of the holidays period.

With 636 patients recruited at the end of 2019 and 429 scans performed, DPMS is in line with its objective to finish enrolling in June 2020.

The target of 300 MCIs has been reached during this period, and the focus is now to be put on SCDs and Dementia patients. This effort is monitored in each site in a weekly basis.

The tracer balance between Vizamyl and Neuraceq is has been stable compared to the previous quarter (45% vs. 55% respectively)

In parallel of the recruitment process, the data management tasks (data cleaning and queries) is being led and the first analysis performed by the dedicated team.

**For more information:** [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

